9M 2023 Financial Performance
9M 2023: APPENDIX
Vyepti
500
400
300
200
37
100
Vyepti revenue
(Quarterly - DKKm)
1,250
+57%
reported
1,000
750
500
250
Wwyepti
Vyepti revenue
(9M - DKKm)
+79%
reported
TM
0
Q3.20
Q3.21
Q3.22
Q3.23
9M 2020 9M 2021 9M 2022 9M 2023
United States
Europe
International Markets
Unless otherwise stated, growth rates are at CER. Vyepti was approved by the FDA February 2020 and by the EU Commission January 2022
Comments
•
Grew 81% (+79% reported) and reached DKK
1.2bn in 9M 2023
• Launched in the U.S., Australia, Canada,
Denmark, Estonia, Finland, Germany, Kuwait,
Singapore, Sweden, Switzerland, U.A.E.,
Austria, U.K., France, Indonesia, Spain, Czech
Republic, Hong Kong, Italy, Norway, Ireland
Additional launches planned for 2023 and
beyond
Vyepti franchise protected for several years:
•
Patents issued lasting to Q3 2037
•
U.S. Composition of matter patent expires in
Q2 2034 (including extensions)View entire presentation